Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,318 papers from all fields of science
Search
Sign In
Create Free Account
Response Evaluation Criteria in Solid Tumors
Known as:
RECIST
An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti‐programmed cell death‐ligand‐1 (PD‐L1) antibody, combined with gefitinib (G): A phase I expansion in TKI‐naïve…
D. Gibbons
,
Laura Qm Chow
,
+7 authors
B. Creelan
Journal of Thoracic Oncology
2016
Corpus ID: 36414628
Highly Cited
2016
Highly Cited
2016
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006.
J. Schachter
,
A. Ribas
,
+17 authors
C. Robert
2016
Corpus ID: 79419130
9504Background: In the phase III KEYNOTE-006 study (NCT01866319), pembro (anti–PD-1) provided superior OS and PFS and a lower…
Expand
Highly Cited
2016
Highly Cited
2016
Updated results for the advanced esophageal carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.
T. Doi
,
S. Piha-Paul
,
+5 authors
J. Bennouna
2016
Corpus ID: 78107572
7 Background: PD-L1 and PD-L2 expression have been associated with poor prognosis in esophageal cancer. Pembrolizumab (pembro) is…
Expand
Highly Cited
2014
Highly Cited
2014
Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.
T. Choueiri
,
M. Fishman
,
+17 authors
M. Sznol
2014
Corpus ID: 79440085
5012 Background: Nivolumab, a fully human IgG4 programmed death-1 (PD-1) inhibitor antibody, has shown encouraging activity in…
Expand
Highly Cited
2012
Highly Cited
2012
The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteria
I. Zerizer
,
A. Al-Nahhas
,
+6 authors
T. Barwick
European Journal of Nuclear Medicine and…
2012
Corpus ID: 28417452
PurposeThis study evaluated the ability of 18F-FDG PET/CT imaging to predict early response to 90Y-radioembolization in…
Expand
Highly Cited
2012
Highly Cited
2012
Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient
A. V. Nuffel
,
D. Benteyn
,
+5 authors
A. Bonehill
Cancer Immunology and Immunotherapy
2012
Corpus ID: 26687693
Dendritic cells (DCs) electroporated with mRNA encoding CD70, CD40L and a constitutively active toll-like receptor 4 (TriMix-DC…
Expand
Review
2006
Review
2006
Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy
A. Barnacle
,
K. McHugh
Pediatric Blood & Cancer
2006
Corpus ID: 42573296
Response evaluation criteria in solid tumors (RECIST) guidelines were published in 2000 to evaluate response to treatment in…
Expand
Review
2006
Review
2006
Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer
B. Monk
,
E. Han
,
Carol A. Josephs-Cowan
,
Gordon Pugmire
,
R. Burger
2006
Corpus ID: 73295685
Highly Cited
2004
Highly Cited
2004
SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial.
R. Motzer
,
B. Rini
,
+7 authors
C. Baum
Journal of Clinical Oncology
2004
Corpus ID: 25352273
4500 Background: SU011248 is an oral multi-targeted tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity…
Expand
2002
2002
Outstanding problems with Response Evaluation Criteria in Solid Tumors (RECIST) in breast cancer
M. Kimura
,
T. Tominaga
Breast Cancer
2002
Corpus ID: 23332135
BackgroundIn 1999 European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States and…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE